Latest News
See all →
ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on…
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
Garching / Munich, February 25, 2026 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that…
Weiterlesen
ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
Garching / Munich, Germany, November 11, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…
Weiterlesen
ITM has one of the deepest, broadest clinical RPT pipelines
Global supply of targeted diagnostic and therapeutic radiopharmaceuticals
Your Career at ITM - Precisely for You
